Antitumor necrosis factor agents in crohn’s disease

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Antitumor necrosis factor (anti-TNF) medications have revolutionized the treatment for Crohn’s disease (CD). The first anti-TNF was approved for CD in 1998, and since then a total of three anti-TNFs are approved by the FDA for use in CD: infliximab, adalimumab, and certolizumab pegol. This chapter will review each anti-TNF with regard to clinical efficacy (induction and maintenance of remission) as well as other key outcomes such as mucosal healing and fistula healing. Additionally this chapter will summarize key differences between the anti-TNFs and review why not all anti-TNFs work to treat CD. Anti-TNF medications have become the standard of care for moderate to severe CD. Understanding the evidence for the various anti-TNFs, as well as the pros and cons of each, is essential for practitioners treating patients with CD.

Original languageEnglish (US)
Title of host publicationTreatment of Inflammatory Bowel Disease with Biologics
PublisherSpringer International Publishing
Pages33-48
Number of pages16
ISBN (Electronic)9783319602769
ISBN (Print)9783319602752
DOIs
StatePublished - Jan 1 2017

Keywords

  • Adalimumab
  • Antitumor necrosis factor
  • Certolizumab pegol
  • Crohn’s disease
  • Infliximab

Fingerprint Dive into the research topics of 'Antitumor necrosis factor agents in crohn’s disease'. Together they form a unique fingerprint.

Cite this